Background
Drug | Identifier | Disease | Phase | Status | Treatment arms | Endpoints |
---|---|---|---|---|---|---|
Trastuzumab | NCT01450696 (HELOISE) | HER2+ gastric cancer | 3 | Completed | a. Capecitabine + cisplatin + trastuzumab (6 mg/kg) b. Capecitabine + cisplatin + trastuzumab (10 mg/kg) | OS a. 12.5 months b. 10.6 months Ctrough increased in high dose trastuzumab |
Trastuzumab | NCT01041404 (ToGA) | HER2+ advanced gastric cancer | 3 | Completed | a. Trastuzumab + fluoropyrimidine + cisplatin b. Fluoropyrimidine + cisplatin | OS a. 13.8 months b. 11.1 months |
Pertuzumab | NCT00545688 (NeoSphere) | HER2+ breast cancer | 2 | Completed | a. Trastuzumab + docetaxel b. Trastuzumab + docetaxel + pertuzumab c. Trastuzumab + pertuzumab d. Pertuzumab + docetaxel | pCR a. 29.0% b. 45.8% c. 16.8% d. 24.0% PFS a. 81% b. 86% c. 73% d. 73% DFS a. 81% b. 84% c. 80% d. 75% |
Pertuzumab | NCT00567190 (CLEOPATRA) | HER2+ metastatic breast cancer | 3 | Completed | a. Pertuzumab + trastuzumab + docetaxel b. Placebo + trastuzumab + docetaxel | OS a. 56.5 months b. 40.8 months PFS a. 18.7 months b. 12.4 months |
Pertuzumab | NCT00976989 (TRYPHAENA) | HER2+ breast cancer | 2 | Completed | a. Pertuzumab + trastuzumab + FEC b. Pertuzumab + trastuzumab + docetaxel + FEC c. Pertuzumab + trastuzumab + docetaxel + carboplatin | pCR a. 61.6% b. 57.3% c. 66.2% CCR a. 50.7% b. 28.0% c. 40.3% |
Pertuzumab T-DM1 | NCT00951665 | HER2+ locally advanced/metastatic breast cancer | 1/2 | Completed | a. T-DM1 3.6 mg/kg (Q3W) + paclitaxel 80 mg/m2 (QW) b. T-DM1 3.6 mg/kg (Q3W) + paclitaxel 80 mg/m2 (QW) + pertuzumab (Q3W) | Total ORR: 50.0% Total CBR: 56.8% Total incidence of grade 3 or worse AEs: 77.3% |
Pertuzumab T-DM1 | NCT00951665 | HER2+ locally advanced/metastatic breast cancer | 1/2 | Completed | a. T-DM1 3.6 mg/kg (Q3W) + paclitaxel 80 mg/m2 (QW) b. T-DM1 3.6 mg/kg (Q3W) + paclitaxel 80 mg/m2 (QW) + pertuzumab (Q3W) | Total ORR: 50.0% Total CBR: 56.8% Total incidence of grade 3 or worse AEs: 77.3% |
T-DM1 | NCT01641939 (GATSBY) | HER2+ advanced gastric cancer | 2/3 | Completed | a. T-DM1 (2.4 mg/kg) b. Standard taxane therapy | Median follow-up a. 17.5 months b. 15.4 months OS a. 7.9 months b. 8.6 months Incidences of grade 3 or more AEs a. 60% b. 70% |
T-DM1 | NCT01120184 (MARIANNE) | HER2+ locally advanced/metastatic breast cancer | 3 | Completed | a. Trastuzumab + taxane b. T-DM1 + pertuzumab c. T-DM1 + placebo | Response rate a. 67.9% b. 59.7% c. 64.2% PFS a. 13.7 months b. 14.1 months c. 15.2 months Incidence of grade 3 or worse AEs a. 54.1% b. 45.4% c. 46.2% |
T-DM1 | NCT00829166 (EMILIA) | HER2+ locally advanced/metastatic breast cancer | 3 | Completed | a. T-DM1 b. Capecitabine + lapatinib | ORR a. 43.6% b. 30.8% PFS a. 9.6 months b. 6.4 months OS a. 30.9 months b. 25.1 months Incidence of grade 3 or worse AEs a. 57% b. 41% |
T-DM1 | NCT01419197 (TH3RESA) | HER2+ breast cancer | 3 | Completed | a. T-DM1 b. Treatment of physician’s choice | OS a. 22.7 months b. 15.8 months PFS a. 6.2 months b. 3.3 months Incidence of grade 3 or worse AEs a. 40% b. 47% |
MM-302 | NCT02213744 (HERMIONE) | HER2+ locally advanced/metastatic breast cancer | 2/3 | Completed | a. MM-302 + trastuzumab b. Chemotherapy of physician’s choice + trastuzumab | OS a. 13.8 months b. 11.1 months |
Drug | Identifier | Disease | Phase | Treatment arms |
---|---|---|---|---|
Trastuzumab | NCT01367002 | HER2+ uterine serous cancer | 2 | a. Carboplatin + paclitaxel + trastuzumab b. Carboplatin + paclitaxel |
Trastuzumab | NCT01196390 | Esophageal cancer | 3 | a. Radiation + chemotherapy + trastuzumab b. Radiation + chemotherapy |
Trastuzumab | NCT01325207 | CNS progression HER2+ breast cancer | 1/2 | Intravenous trastuzumab |
Trastuzumab | NCT02030561 | HER2+ breast and gastric cancer | 1/2 | Trastuzumab + NK cells |
Trastuzumab | NCT02598310 | HER2+/ER− operable breast cancer | 2 | Nab-paclitaxel + trastuzumab |
Trastuzumab | NCT01340430 | HER2+ breast cancer | 2 | FEC + paclitaxel + trastuzumab |
Trastuzumab | NCT01785420 | HER2+ operable breast cancer | 3 | a. Trastuzumab b. Placebo |
Trastuzumab | NCT02152943 | HR−/HER2+ advanced cancers | 1 | Everolimus + letrozole + trastuzumab |
Trastuzumab | NCT01950182 (SYSUCC-002) | Luminal B2 breast cancer | 3 | a. Trastuzumab + chemotherapy b. Endocrine therapy + trastuzumab |
Trastuzumab | NCT01873833 | HER2+ metastatic breast cancer | 2 | Chemotherapy + lapatinib ditosylate + trastuzumab |
Pertuzumab | NCT01996267 (TRAIN-2) | HER2+ breast cancer | 3 | a. FEC-T + pertuzumab b. PTC + pertuzumab |
Pertuzumab | NCT01572038 (PERUSE) | HER2+ breast cancer | 3 | Pertuzumab + trastuzumab + taxane |
Pertuzumab | NCT02229149 | HER2+ metastatic breast cancer | 2 | a. Chemotherapy + trastuzumab + pertuzumab b. Chemotherapy + trastuzumab |
Pertuzumab | NCT02896855 | HER2+ metastatic breast cancer | 3 | a. Pertuzumab + trastuzumab + docetaxel b. Placebo + trastuzumab + docetaxel |
Pertuzumab | NCT02625441 | HER2+ early breast cancer | 3 | a. Pertuzumab + trastuzumab + docetaxel b. Trastuzumab + docetaxel |
Trastuzumab Pertuzumab | NCT02139358 | HER2+ metastatic breast cancer | 1/2 | Gemcitabine + trastuzumab + pertuzumab |
Trastuzumab Pertuzumab | NCT01774786 | HER2+ gastric or gastroesophageal junction cancer | 3 | Pertuzumab + trastuzumab + chemotherapy |
Trastuzumab Pertuzumab | NCT02536339 | CNS progression HER2+ breast cancer | 2 | Pertuzumab + high-dose trastuzumab |
Trastuzumab Pertuzumab | NCT02598427 | CNS progression HER2+ breast cancer | 1 | Intrathecal + pertuzumab + trastuzumab |
Trastuzumab Pertuzumab | NCT02581462 | HER2+ gastric or gastroesophageal cancer | 2/3 | a. FLOT b. FLOT + trastuzumab + pertuzumab |
Trastuzumab Pertuzumab | NCT02436993 | Breast cancer | 2 | a. Carboplatin + paclitaxel + bevacizumab (HER2−) b. Carboplatin + paclitaxel + trastuzumab + pertuzumab (HER2+) |
Trastuzumab Pertuzumab | NCT02411344 | HER2+/HR+ breast cancer | 2 | Pertuzumab + trastuzumab + letrozole |
T-DM1 Pertuzumab | NCT02326974 | HER2+ breast cancer | 2 | T-DM1 + pertuzumab |
T-DM1 | NCT02414646 | HER2+ breast cancer | 2 | T-DM1 |
T-DM1 | NCT02675829 | HER2 amplified or mutant cancers | 2 | T-DM1 |
T-DM1 | NCT01702571 | HER2+ locally advanced/metastatic breast cancer | 3 | T-DM1 |
T-DM1 | NCT02289833 | HER2+ locally advanced/metastatic NSCLC | 2 | T-DM1 |
T-DM1 | NCT01966471 | HER2+ primary breast cancer | 3 | a. T-DM1 + pertuzumab b. Trastuzumab + pertuzumab + taxane |
T-DM1 | NCT01772472 (KATHERINR) | HER2+ breast cancer | 3 | a. T-DM1 b. Trastuzumab |
MGAH22 | NCT01148849 | HER2+ cancers | 1 | MGAH22 (margetuximab) |
MGAH22 | NCT02492711 (SOPHIA) | HER2+ metastatic breast cancer | 3 | a. Margetuximab + chemotherapy b. Trastuzumab + chemotherapy |
MGAH22 | NCT02689284 | HER2+ gastric or gastroesophageal junction cancer | 1/2 | Margetuximab + pembrolizumab |
XMT-1522 | NCT02952729 | HER2+ breast cancer, NSCLC and gastric cancer | 1 | XMT-1522 |
DS-8201a | NCT02564900 | Advanced solid tumors | 1 | DS-8201a |
SYD985 | NCT02277717 | Locally advanced/metastatic solid tumors | 1 | SYD985 |
Drug | Targets | Diseases | Treatment arms | Phase | Status | Identifier |
---|---|---|---|---|---|---|
Ertumaxomab | HER2/CD3 | Metastatic breast cancer | Ertumaxomab | 2 | Terminated | NCT00452140 |
Ertumaxomab | HER2/CD3 | Metastatic breast cancer | Ertumaxomab | 2 | Terminated | NCT00522457 |
Ertumaxomab | HER2/CD3 | Her2+ advanced solid tumors | Ertumaxomab | 1/2 | Terminated | NCT01569412 |
MM-111 | HER2/HER3 | Her2+, heregulin+, breast cancer | MM-111 | 1 | Completed | NCT00911898 |
MM-111 | HER2/HER3 | Her2+, heregulin+, breast cancer | MM-111 + trastuzumab | 1 | Completed | NCT01097460 |
MM-111 | HER2/HER3 | HER2+ solid tumors | a. Cisplatin + capecitabin + trastuzumab + MM-111 b. Lapatinib ± trastuzumab + MM-111 c. Paclitaxel + trastuzumab + MM-111 d. Lapatinib + trastuzumab + paclitaxel + MM-111 e. Docetaxel + trastuzumab + MM-111 | 1 | Completed | NCT01304784 |
MM-111 | HER2/HER3 | HER2+ esophagus cancer, gastroesophageal junction cancer, stomach cancer | a. MM-111 + paclitaxel + trastuzumab b. Paclitaxel + trastuzumab | 2 | Completed | NCT01774851 |
HER2Bi-aATC | HER2/CD3 | Her2+ neoplasms of digestive system | Interleukin-2 + HER2Bi-aATC | 1 | Recruiting | NCT02662348 |
MCLA-128 | HER2/HER3 | HER2+ malignant solid tumors | a. MCLA-128 dose escalation b. MCLA-128 for breast cancer c. MCLA-128 for ovarian cancer d. MCLA-128 for gastric/GE junction cancer e. MCLA-128 for endometrial cancer f. MCLA-128 for NSCLC | 1/2 | Recruiting | NCT02912949 |
GBR1302 | HER2/CD3 | HER2+ solid tumors | GBR1302 | 1 | Recruiting | NCT02829372 |
ZW25 | Two different epitopes of HER2 | HER2+ solid tumors | ZW25 | 1 | Recruiting | NCT02892123 |